UK secures 480,000 courses of Molnupiravir and 250,000 of Ritonavir pending approval
The UK government has signed agreements to secure 480,000 courses of Molnupiravir from Merck Sharp and Dohme and 250,000 courses of Ritonavir from Pfizer, pending regulatory approval. Both treatments are intended for at-risk individuals with mild to moderate COVID-19 symptoms.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthUK secures 480,000 courses of Molnupiravir and 250,000 of Ritonavir pending approval
Sign in or subscribeBrowse free archive reportsThe UK government has signed agreements to secure 480,000 courses of Molnupiravir from Merck Sharp and Dohme and 250,000 courses of Ritonavir from Pfizer, pending regulatory approval. Both treatments are intended for at-risk individuals with mild to moderate COVID-19 symptoms.